

Bernard Verrier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6452757/publications.pdf>

Version: 2024-02-01

45
papers

2,146
citations

236612

25
h-index

233125

45
g-index

45
all docs

45
docs citations

45
times ranked

3118
citing authors

#	ARTICLE	IF	CITATIONS
1	A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response. <i>Pharmaceutics</i> , 2022, 14, 107.	2.0	3
2	Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepared by Automated Microfluidic System and Bulk Method. <i>Pharmaceutics</i> , 2022, 14, 1297.	2.0	2
3	Design and Evaluation of Autophagy-Inducing Particles for the Treatment of Abnormal Lipid Accumulation. <i>Pharmaceutics</i> , 2022, 14, 1379.	2.0	4
4	Biodistribution of surfactant-free poly(lactic-acid) nanoparticles and uptake by endothelial cells and phagocytes in zebrafish: Evidence for endothelium to macrophage transfer.. <i>Journal of Controlled Release</i> , 2021, 331, 228-245.	4.8	8
5	Seaweed Sulfated Polysaccharides against Respiratory Viral Infections. <i>Pharmaceutics</i> , 2021, 13, 733.	2.0	15
6	Autophagy and Mitophagy-Related Pathways at the Crossroads of Genetic Pathways Involved in Familial Sarcoidosis and Host-Pathogen Interactions Induced by Coronaviruses. <i>Cells</i> , 2021, 10, 1995.	1.8	9
7	Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 945-956.	2.3	21
8	Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. <i>Trends in Molecular Medicine</i> , 2020, 26, 311-323.	3.5	203
9	Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery. <i>Pharmaceutical Research</i> , 2020, 37, 30.	1.7	31
10	New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses. <i>EBioMedicine</i> , 2020, 58, 102922.	2.7	19
11	Development of an antibacterial nanocomposite hydrogel for human dental pulp engineering. <i>Journal of Materials Chemistry B</i> , 2020, 8, 8422-8432.	2.9	29
12	Molecular modelling of TLR agonist Pam3CSK4 entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality. <i>International Journal of Pharmaceutics</i> , 2019, 568, 118569.	2.6	11
13	Self-assembled amphiphilic copolymers as dual delivery system for immunotherapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 232-239.	2.0	10
14	Recombinant Haemagglutinin Derived From the Ciliated Protozoan <i>Tetrahymena thermophila</i> Is Protective Against Influenza Infection. <i>Frontiers in Immunology</i> , 2019, 10, 2661.	2.2	2
15	Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. <i>Biomaterials</i> , 2019, 195, 23-37.	5.7	132
16	Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses. <i>Journal of Immunology</i> , 2017, 198, 4205-4209.	0.4	34
17	Improving bioassay sensitivity through immobilization of bio-probes onto reactive micelles. <i>Chemical Communications</i> , 2017, 53, 8062-8065.	2.2	5
18	Antibiotic incorporation in jet-sprayed nanofibrillar biodegradable scaffolds for wound healing. <i>International Journal of Pharmaceutics</i> , 2017, 532, 802-812.	2.6	18

#	ARTICLE	IF	CITATIONS
19	Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. <i>Vaccines</i> , 2016, 4, 34.	2.1	101
20	Triggering Intracellular Receptors for Vaccine Adjuvantation. <i>Trends in Immunology</i> , 2016, 37, 573-587.	2.9	54
21	First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. <i>Journal of Immunology</i> , 2016, 197, 1979-1988.	0.4	1
22	Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 214-222.e2.	1.5	30
23	Controlled association and delivery of nanoparticles from jet-sprayed hybrid microfibrillar matrices. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 140, 142-149.	2.5	10
24	Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. <i>Biomaterials</i> , 2016, 75, 327-339.	5.7	43
25	Micelle-Based Adjuvants for Subunit Vaccine Delivery. <i>Vaccines</i> , 2015, 3, 803-813.	2.1	51
26	Preparation and In Vitro Evaluation of Imiquimod Loaded Polylactide-based Micelles as Potential Vaccine Adjuvants. <i>Pharmaceutical Research</i> , 2015, 32, 311-320.	1.7	31
27	Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. <i>Nanomedicine</i> , 2014, 9, 2703-2718.	1.7	98
28	Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. <i>Vaccine</i> , 2014, 32, 6266-6276.	1.7	20
29	Cutting Edge: New Chimeric NOD2/TLR2 Adjuvant Drastically Increases Vaccine Immunogenicity. <i>Journal of Immunology</i> , 2014, 193, 5781-5785.	0.4	59
30	Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells. <i>Journal of Controlled Release</i> , 2014, 176, 115-122.	4.8	25
31	Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. <i>Journal of Controlled Release</i> , 2013, 167, 60-67.	4.8	79
32	Secretory IgA specific for MPER can protect from HIV-1 infection in vitro. <i>Aids</i> , 2013, 27, 1992-1995.	1.0	12
33	Elaboration of Glycopolymer-Functionalized Micelles from an N-Vinylpyrrolidone/Lactide-Based Reactive Copolymer Platform. <i>Macromolecular Bioscience</i> , 2013, 13, 1213-1220.	2.1	24
34	Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex. <i>Aids</i> , 2013, 27, 717-730.	1.0	14
35	Intradermal Immunization Triggers Epidermal Langerhans Cell Mobilization Required for CD8 T-Cell Immune Responses. <i>Journal of Investigative Dermatology</i> , 2012, 132, 615-625.	0.3	61
36	Neutrophils Transport Antigen from the Dermis to the Bone Marrow, Initiating a Source of Memory CD8+ T Cells. <i>Immunity</i> , 2012, 37, 917-929.	6.6	160

#	ARTICLE	IF	CITATIONS
37	Stability of polylactic acid particles and release of fluorochromes upon topical application on human skin explants. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 80, 76-84.	2.0	32
38	Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. <i>Vaccine</i> , 2011, 29, 6379-6391.	1.7	57
39	Elaboration of densely functionalized polylactide nanoparticles from <i>N</i> -acryloxysuccinimide-based block copolymers. <i>Journal of Polymer Science Part A</i> , 2011, 49, 1341-1350.	2.5	22
40	Investigation of Polylactic Acid (PLA) Nanoparticles as Drug Delivery Systems for Local Dermatotherapy. <i>Pharmaceutical Research</i> , 2009, 26, 2027-2036.	1.7	208
41	Nanoparticle-Based Targeting of Vaccine Compounds to Skin Antigen-Presenting Cells By Hair Follicles and their Transport in Mice. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1156-1164.	0.3	114
42	Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. <i>Vaccine</i> , 2009, 27, 5284-5291.	1.7	57
43	Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. <i>Vaccine</i> , 2007, 25, 7491-7501.	1.7	37
44	Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. <i>Journal of Controlled Release</i> , 2006, 112, 175-185.	4.8	117
45	Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. <i>Journal of Controlled Release</i> , 2006, 115, 57-67.	4.8	73